Description: In late 2021, U.S. Congress passed the Consolidated Appropriations Act (CCA), which requires group health plans and health insurers to submit information regarding the costs of prescription drug costs and other health care services each year to the federal government. Learn how this data can be useful to anyone responsible for forecasting and budgeting.

Description: SARS-CoV2 will impact our post-pandemic future. Morbidity more than mortality will impact the life and health business in the mid-term. But how does this temporary disruption in health care elicit long-tail implications on other common diseases and changes in lifestyles? Find out how mid-term pricing could be affected using one case scenario and also show how mental health will particularly shape the post-pandemic future (individually and societal), not only due to long COVID. Review the experience of the insured policies and discuss future ideas for COVID-19 research at the Society of Actuaries Research Institute. Consider recent causes of death studies, as well as reported claims analyses to help expedite the analysis of recent experience. Join us where experts from both the medical and actuarial disciplines join forces to discuss this important topic.

Description: Discover the impact of COVID-19 on member costs post diagnosis and the future of mortality in this Emerging Long Term COVID-19 Trends webcast. This webcast will be split up into Health and Life portions. During the Health portion of this webcasts, you will learn more about the impact on risk scores due to recent findings. Enjoy this discussion and further dive into the emerging COVID-19 trends that may affect how you conduct business practices. At the Life portion, the SOA Research Institute assembled a panel of mortality experts who will express opinions on the effects of the U.S. mortality rate for general, insured and pension populations in the short-term.

Description: Hear from Kevin Pierce, FSA MAAA on the key components on the Inflation Reduction Act as it relates to Medicare Part D. Kevin is a Senior Consulting Actuary at Milliman and a top industry speaker on this subject. Kevin has extensive industry experience in actuarial, finance, and strategic projects, providing market intelligence and strategy support for clients across the health care industry. He outlines key provisions of the act, such as a complete redesign of the benefit, inflation rebate payments from pharmaceutical manufacturers,, and Medicare’s ability to negotiate drug prices. Kevin touches on the changes in costs and complexities for beneficiaries, pharmaceutical manufacturers, the federal government, and health insurers. Contributors: Kevin Pierce, FSA MAAA, Mitchell Momanyi, FSA, MAAA, Deana Bell, FSA, MAAA, Jon Forster, ASA, MAAA

Description: COVID-19 had a major impact on mortality over the last several years both for the U.S. population and the insured population. Discuss excess deaths from both COVID-19 and other causes of death that have been observed during the pandemic. Review the trends seen in both the U.S population and the insured population’s deaths as well as a medical perspective as to what led to these changes in excess deaths that were not directly caused by COVID-19. Hear about predictions of what to expect for future mortality as a result of the COVID-19 pandemic. By attending the session, you will:•Identify drivers of excess deaths in both the U.S. population and insured population as a result of the COVID-19 pandemic.•Understand changes in the U.S. population’s health and behaviors that have contributed to these drivers.•Apply theses learnings when considering impacts to future mortality for the insured population.

Description: As an increasing number of insurance companies, both traditional and startup, attempt to attract new customers, we see waves of product innovation ideas with goals to break into the under and un-insured markets. Some of these ideasare intended to be served as alternatives to traditional insurance focusing on adding enhancements to existing products ranging from flexible benefit design to accelerated underwriting. Others look to engage and attract new customers through a streamlined sales process in order to cultivate customer relationships and increase brand recognition. Explore how innovative companies break through obstacles from both the actuarial and compliance standpoint to bring new solutions to the marketplace. By attending the session, you will: - Understand types of innovation taking place in the life insurance industry. - Provide ideas for product of the future. - Learn different aspects of innovation on life insurance such as distribution, cost and compliance.

Description: Management service organizations (MSOs) in value-based care have expanded into far more locations in the health care ecosystem; some demonstrate value to both buyers and providers. Explore the role of these players in the health care ecosystem, their future outlook, and how actuaries can help them perform.

Description: The U.S. health care system continues to have its problems. It costs too much and even with public policy developments we are not meeting the desired objectives. What's next? What else can we do? Discuss some of the emerging ideas that are being pursued and the likelihood of their success at solving our collective problem.

Description: Arun Paul, FSA MAAA Pricing Actuary for Canada Life Re-Insurance discusses morbidity as it relates to Long-Term Care Insurance. Arun is the current President of SANA The South Asian Network of Actuaries and has over a decade worth of actuarial experience. He provides insights into how morbidity is defined in Long-Term Care insurance and explains the process of filing and processing claims in this engaging discussion with Jon Forster, ASA MAAA Professional Development Learning and Content Design Director at the Society of Actuaries. They also touch upon key factors affecting Long-Term Care insurance costs, such as care duration, benefits administration, and the impact of geographic location and prior claim history on claim costs. Contributors: ARun Paul FSA MAAA, Julite Spector, FSA, MAAA Matt Morton FSA MAAA, RAchael Marsiglio FSA MAAA , Jon Forster ASA MAAA

Description: The time has arrived for ASU 2018-12, otherwise known as Long-Duration Targeted Improvements (LDTI). For health insurance products, the ASU will require considerable efforts to make the necessary changes to valuation systems, procedures, assumptions, and/or methodologies in order to be in compliance. Learn about LDTI implications specific to carriers of long-term care and supplemental health products, including the impact of combining active life reserves and claim reserves in Liability for Future Policy Benefits (LFPB), changes to how attained age rated products will be approached, allocating and discounting the claim liability (IBNR), and how the treatment of Profits Followed by Losses (PFBL) will evolve under LDTI.